177 related articles for article (PubMed ID: 34546360)
1. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.
Sandborn WJ; Lewis JD; Panes J; Loftus EV; D'Haens G; Yu Z; Huang B; Lacerda AP; Pangan AL; Feagan BG
J Crohns Colitis; 2022 Mar; 16(3):444-451. PubMed ID: 34546360
[TBL] [Abstract][Full Text] [Related]
2. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Peyrin-Biroulet L; Louis E; Loftus EV; Lacerda A; Zhou Q; Sanchez Gonzalez Y; Ghosh S
Adv Ther; 2021 May; 38(5):2339-2352. PubMed ID: 33755884
[TBL] [Abstract][Full Text] [Related]
3. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data.
Feagan B; Sandborn WJ; Rutgeerts P; Levesque BG; Khanna R; Huang B; Zhou Q; Maa JF; Wallace K; Lacerda A; Thakkar RB; Robinson AM
Inflamm Bowel Dis; 2018 Apr; 24(5):932-942. PubMed ID: 29668919
[TBL] [Abstract][Full Text] [Related]
4. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
6. End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease.
Wong ECL; Buffone E; Lee SJ; Dulai PS; Marshall JK; Reinisch W; Narula N
J Crohns Colitis; 2021 Jul; 15(7):1114-1119. PubMed ID: 33245751
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
Lewis JD; Rutgeerts P; Feagan BG; D'haens G; Danese S; Colombel JF; Reinisch W; Rubin DT; Selinger C; Bewtra M; Barcomb L; Lacerda AP; Wallace K; Butler JW; Wu M; Zhou Q; Liao X; Sandborn WJ
Inflamm Bowel Dis; 2020 Jan; 26(2):304-313. PubMed ID: 31644790
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for induction of remission in Crohn's disease.
Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
12. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
Colombel JF; Schreiber S; D'Haens G; Rizzo J; Kligys K; Griffith J; Zambrano J; Zhou Q; Zhang Y; Kalabic J; Rieder F; Dubinsky MC; Panaccione R
J Crohns Colitis; 2024 Jun; 18(6):818-827. PubMed ID: 38069472
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.
Panaccione R; Colombel JF; Sandborn WJ; D'Haens G; Zhou Q; Pollack PF; Thakkar RB; Robinson AM
Aliment Pharmacol Ther; 2013 Nov; 38(10):1236-47. PubMed ID: 24134498
[TBL] [Abstract][Full Text] [Related]
14. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents.
Herrera-deGuise C; Casellas F; Robles V; Navarro E; Borruel N
J Gastroenterol Hepatol; 2015 Feb; 30(2):286-91. PubMed ID: 25302652
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Panaccione R; Schreiber S; Byczkowski D; Li J; Kent JD; Pollack PF
Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab induces deep remission in patients with Crohn's disease.
Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
[TBL] [Abstract][Full Text] [Related]
18. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
[TBL] [Abstract][Full Text] [Related]
19. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
20. Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
Chugh R; Braga-Neto MB; Fredrick TW; Ramos GP; Terdiman J; El-Nachef N; Loftus EV; Mahadevan U; Kane SV
J Crohns Colitis; 2023 Apr; 17(4):504-512. PubMed ID: 36272109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
